Streamlining Drug Development and Manufacturing with End-to-End CDMO Partnerships
May 24, 2022
Efficiently developing drugs and getting them to patients requires careful optimization of drug development, manufacturing, and supply processes. Small to mid-size companies may struggle to synchronize the process efficiently, especially with uncertainty and disruption from tumultuous current events. To do so, many outsource to contract and development manufacturing organizations (CDMOs). A new white paper by Cambrex and Pharma Intelligence explores how companies can choose and structure the best CDMO partnerships for their needs.
According to the white paper, “Among small biopharma companies, 57% and a further 14%, respectively, said they were outsourcing more than half or 31-40% of all drug development. Cost efficiency clearly factored into these decisions, with 51% of survey respondents who outsourced at least part of their drug development saying they had made cost savings since outsourcing; only 13% had not.”
To learn more, click here.
(Source: Cambrex, May 24th, 2022)